Abstract 3016
Background
Although dedicated breast PET (DbPET) visualizes sub-centimeter breast cancer lesions and intratumoral heterogeneity, the impact of histology on the detectability of DbPET remains unknown.
Methods
This study included 455 patients with breast cancer, who underwent whole-body PET (WBPET) and ring-type DbPET between January 2016 and March 2018. The relationship of histology and sensitivities of WBPET and DbPET for breast cancer was assessed.
Results
The median patient age was 57 years and histology was as follows: 82 (18.0%) noninvasive carcinoma, 18 (4.0%) microinvasive carcinoma, 305 (67.0%) invasive carcinoma with no special type, 9 (2.0%) invasive lobular carcinoma, and 41 (9.0%) other types. The sensitivity of WBPET and DbPET was 74.5% and 93.2%, respectively. The sensitivities of each histology on WBPET/DbPET were 41.5%/78.0%, 72.2%/100%, 83.9%/96.7%, 44.4%/88.9%, and 78.0%/95.1%, respectively (Table). The sensitivity was low on WBPET in noninvasive, microinvasive, invasive lobular, mucinous and tubular carcinomas. Lobular carcinoma in situ had low sensitivity on both WBPET and DbPET imaging. In the multivariate analysis, undetectable tumor factors on WBPET were sub-centimeter tumor size (Odds ratio [OR] = 6.04, P < 0.001) and histology (OR = 1.69, P = 0.08); for DbPET, Ki-67 labeling index was an undetectable tumor factor (OR = 4.32, P = 0.039).Table: 1343P
Sensitivities of whole-body and dedicated breast PET according to histology
| N | Sensitivity (%) | P | ||
|---|---|---|---|---|
| WbPET | DbPET | |||
| Total | 455 | 339 (74.5) | 424 (93.2) | < 0.001 |
| Noninvasive carcinoma | 82 | 34 (41.5) | 64 (78.0) | < 0.001 |
| Ductal carcinoma in situ | 72 | 32 (44.4) | 61 (84.7) | < 0.001 |
| Lobular carcinoma in situ | 8 | 1 (12.5) | 2 (25.0) | 1 |
| Others | 2 | 1 (50.0) | 1 (50.0) | 1 |
| Microinvasive carcinoma | 18 | 13 (72.2) | 18 (100) | 0.046 |
| Invasive carcinoma of no special type | 305 | 256 (83.9) | 295 (96.7) | < 0.001 |
| Invasive lobular carcinoma | 9 | 4 (44.4) | 8 (88.9) | 0.131 |
| Others | 41 | 32 (78.0) | 39 (95.1) | 0.048 |
| Mucinous carcinoma | 19 | 13 (68.4) | 18 (94.7) | 0.09 |
| Tubular carcinoma | 5 | 3 (60.0) | 4 (80.0) | 0.444 |
| Carcinoma with apocrine differentiation | 5 | 5 (100) | 5 (100) | 1 |
| Invasive micropapillary carcinoma | 5 | 5 (100) | 5 (100) | 1 |
| Others | 7 | 6 (85.7) | 7 (100) | 1 |
Conclusions
Breast cancers with the specific histological subtypes are hard to detect on WBPET. DbPET can overcome the factors for weak WBPET detectability, such as tumor size and histology, and might prevent the overdiagnosis of lobular carcinoma in situ.
Clinical trial identification
Legal entity responsible for the study
Hiroshima University.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3816 - A prediction panel with DNA methylation biomarkers for lung adenocarcinoma
Presenter: Nan Shen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5242 - Novel genomic classifier for early stage colorectal cancer patients
Presenter: Elisabeth Letellier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5404 - Baseline Blood Immune Profiling to Predict Response to antiPD-1 in Patients with Advanced Non-Small Cell Lung Cancer
Presenter: Emanuela Romano
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5462 - Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient Mismatch Repair (pMMR) colorectal and endometrial cancers.
Presenter: Justine Cohen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5465 - Immune prognostic index (IPI) and Hyper-Progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in Phase 1 trials (Ph1T): can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?
Presenter: Ignacio Matos Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5742 - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
Presenter: Maria Silvia Cona
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5790 - Effects of concomitant genetic alterations on cancer patient overall survival
Presenter: Yu Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5144 - Circulating Exosomal Integrin _v_5 Predicts Liver Metastasis and Prognosis in Human Colorectal Cancer
Presenter: Dake Chu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5149 - Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for Non-Small Cell Lung Cancer patients?
Presenter: Rosalinda Sorrentino
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5673 - Smokers and COPD patients have high circulating caspase-4 levels: is it an alarm?
Presenter: Michela Terlizzi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract